4% Tetrasodium EDTA Lock Reduces CVAD Complications in ICU Adults

Enhancing Central Venous Access Device Safety in Critical Care

Central venous access devices (CVADs) are ubiquitous in intensive care units, serving as essential conduits for medications, nutrition, and monitoring [1, 2]. Despite their utility, these devices carry significant risks, including catheter-associated bloodstream infections, occlusions, and venous thrombosis [1, 3, 4]. Such complications can compromise patient safety and extend hospital stays, increasing healthcare costs [3, 5]. Standard care often involves locking inactive catheter lumens with saline or citrate, but these solutions provide minimal protection against the bacterial biofilms and fibrin sheaths that frequently lead to device failure [1, 6]. This gap in prevention highlights a persistent clinical need for a more effective locking solution to maintain CVAD patency and reduce infection rates [7, 8].

Understanding the Mechanism: How EDTA Addresses CVAD Risks

To address the common complications of central venous access devices (CVADs), researchers have investigated ethylenediaminetetraacetic acid (EDTA), a synthetic amino acid with a unique combination of properties. As a locking fluid instilled into inactive CVAD ports, EDTA offers a multi-pronged strategy for device maintenance. Its function as a potent anticoagulant directly counters the formation of thrombi, a primary cause of catheter-related venous thrombosis. Furthermore, its established antimicrobial and antibiofilm activities work to prevent the colonization of microorganisms and the development of resilient biofilms within the catheter lumen, which are precursors to both bloodstream infections and certain types of occlusions. By targeting the key pathological processes of thrombosis and infection simultaneously, EDTA is hypothesized to preserve catheter patency and reduce device-related morbidity.

Trial Design and Patient Cohort

To assess the real-world effectiveness of a 4% tetrasodium EDTA (t-EDTA) locking solution, investigators conducted a pragmatic, triple-blind, multicenter, cluster-randomized crossover trial. The pragmatic design ensured the intervention was tested under typical ICU conditions. The study took place in 6 Canadian hospitals, including 3 community and 3 academic centers, enhancing the generalizability of the results. The trial employed a cluster-randomized crossover method, where entire ICUs (the clusters) were randomized to use either t-EDTA or a control solution for a 3.5-month period, and then switched to the opposite group after a 1-month follow-up. This powerful design allows each ICU to serve as its own control, minimizing variability between sites. Triple-blinding meant that patients, clinicians, and data analysts were all unaware of treatment assignments. The study enrolled 1468 adults older than 18 years with a CVAD in place that had at least one unused lumen. For the intervention, prefilled, masked syringes contained 2.5 mL of t-EDTA, while the control group received standard care with saline or 4% citrate for hemodialysis lines. The primary outcome was a composite incidence rate of CVAD-associated bloodstream infection, catheter occlusion requiring alteplase, and catheter removal due to occlusion. Enrollment began on March 22, 2022, with final follow-up on September 25, 2024.

Key Findings: Reduced Composite Outcome and Specific Occlusion Rates

The final analysis included 1468 patients (mean age, 60 years; 37.7% female), with 696 receiving the tetrasodium EDTA (t-EDTA) locking fluid and 772 receiving the control solution. The study found a clinically meaningful reduction in the primary composite outcome. The incidence rate of CVAD-associated bloodstream infection, occlusion requiring alteplase, or catheter removal for occlusion was 13.1 per 1000 catheter-days in the t-EDTA group, compared with 19.9 per 1000 catheter-days in the control group. After adjustment in a multivariate analysis, this translated to a significant reduction in the composite outcome for patients receiving t-EDTA (rate ratio, 0.68; 95% CI, 0.47-0.96; P = .03). When the researchers examined the individual components of this primary outcome, they found the effect was driven by one specific factor. Of the three components, only the rate of CVAD occlusion requiring alteplase administration differed significantly between the groups. The t-EDTA group experienced 66 such events (11.67 per 1000 catheter-days), while the control group had 112 events (17.73 per 1000 catheter-days). This represents a 34% relative reduction in occlusions needing thrombolytic treatment in the t-EDTA group (rate ratio, 0.66; 95% CI, 0.46-0.96).

Clinical Implications for CVAD Management

The results of this trial suggest that using a 4% tetrasodium EDTA (t-EDTA) locking solution can reduce major complications associated with central venous access devices (CVADs) in adult ICU patients. The observed reduction in the composite outcome of infection and occlusion was primarily driven by a substantial decrease in the incidence of catheter occlusions that necessitated intervention with alteplase. For the practicing clinician, this finding is directly applicable. Adopting 4% t-EDTA as a standard locking fluid for inactive CVAD lumens could decrease the frequency of catheter blockages, thereby reducing the need for thrombolytic agents, saving nursing time, and minimizing treatment delays. By maintaining more reliable vascular access, this practice may improve the longevity of indwelling catheters and lower the resource burden associated with managing CVAD dysfunction. The trial is registered with ClinicalTrials.gov, identifier NCT04548713, for further review.

References

1. Ornowska M, Wong H, Ouyang Y, et al. Control of Line Complications with KiteLock (CLiCK) in the critical care unit: study protocol for a multi-center, cluster-randomized, double-blinded, crossover trial investigating the effect of a novel locking fluid on central line complications in the critical care population. Trials. 2022. doi:10.1186/s13063-022-06671-5

2. Wang S, O’Daniel EL. Updates in Intestinal Failure Management. Journal of Clinical Medicine. 2025. doi:10.3390/jcm14093031

3. Ullman A, Gibson V, Takashima M, et al. Pediatric central venous access devices: practice, performance, and costs. Pediatric Research. 2022. doi:10.1038/s41390-022-01977-1

4. Hyun A, Takashima M, Souza SD, et al. Central venous access device management for children undergoing treatment for blood disorders and cancer: a descriptive international cross-sectional survey. Supportive Care in Cancer. 2025. doi:10.1007/s00520-025-09240-z

5. Samaras P, Dold S, Braun J, et al. Infectious Port Complications Are More Frequent in Younger Patients with Hematologic Malignancies than in Solid Tumor Patients. Oncology. 2008. doi:10.1159/000151393

6. Sauer K, Steczko J, Ash SR. Effect of a solution containing citrate/Methylene Blue/parabens on Staphylococcus aureus bacteria and biofilm, and comparison with various heparin solutions. Journal of Antimicrobial Chemotherapy. 2009. doi:10.1093/jac/dkp060

7. Alfieri A, Franco SD, Passavanti MB, et al. Antimicrobial Lock Therapy in Clinical Practice: A Scoping Review. Microorganisms. 2025. doi:10.3390/microorganisms13020406

8. Hill J, Garner R. Efficacy of 4% tetrasodium ethylenediaminetetraacetic acid (T-EDTA) catheter lock solution in home parenteral nutrition patients: A quality improvement evaluation. Journal of Vascular Access. 2020. doi:10.1177/1129729820946916